Drug
Ocrelizumab CO Formulated With Rhuph20
Ocrelizumab CO Formulated With Rhuph20: highest development phase Phase 1, developed by Roche. 1 trial record tracked on RxWires.
- Highest phase
- Phase 1
- Developer
- Roche
Trials
| Drug | Phase | Indication |
|---|---|---|
| Ocrelizumab Co-formulated With rHuPH20 NCT07667322 | Phase 1 | Multiple Sclerosis |
Latest
No recent events.
Follow Ocrelizumab CO Formulated With Rhuph20 on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.